Neurochlore Overview

  • Founded
  • 2011

  • Status
  • Private

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 3

Neurochlore General Information


Developer of a neuro-therapeutic treatment platform intended to treat autism spectrum disorders. The company's platform develops new therapeutic approaches to ameliorate neurological and psychiatric diseases based on the regulation of the brain's electrical activity around a wide range of animal models of ASD and syndromes with associated autism, enabling patients to modulate intracellular chloride.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Other Healthcare Technology Systems
Primary Office
  • 163 Avenue de Luminy
  • Zone Luminy Biotech, Case 922, Cedex 09
  • 13273 Marseille
  • France

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neurochlore Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Secondary Transaction - Private 01-Aug-2022 00.000 Completed Clinical Trials - Phase 3
3. Early Stage VC 18-Jul-2013 00.000 00.000 00.00 Completed Startup
2. Accelerator/Incubator Completed Startup
1. Grant 12-Nov-2012 Completed Startup
To view Neurochlore’s complete valuation and funding history, request access »

Neurochlore Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A Preferred 0,000 000.000000 00000.00 00000.00 00 00000.00 00.000
Ordinary 000 000.000000 000.00 000.00 00 000.00 0.000
To view Neurochlore’s complete cap table history, request access »

Neurochlore Patents

Neurochlore Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220370390-A1 Liquid oral formulation of bumetanide Pending 31-Oct-2019 0000000000
EP-4051232-A1 Liquid oral formulation of bumetanide Pending 31-Oct-2019 0000000000
CA-3158575-A1 Liquid oral formulation of bumetanide Pending 31-Oct-2019 A61K31/196

Neurochlore Executive Team (3)

Name Title Board Seat Contact Info
Constance Ben-Ari Co-Chief Executive Officer
Yehezkel Ben-Ari Ph.D Co-Founder, Co-Chief Executive Officer, President & Board Member
You’re viewing 2 of 3 executive team members. Get the full list »

Neurochlore Board Members (2)

Name Representing Role Since
Eric Lemonnier Ph.D Neurochlore Co-Founder & Board Member 000 0000
Nouchine Hadjikhani Ph.D Neurochlore Co-Founder & Board Member 000 0000
To view Neurochlore’s complete board members history, request access »

Neurochlore Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
L'Agence Nationale de la Recherche Government 000 0000 000000 0
Grand Luminy Accelerator/Incubator Minority 000 0000 000000 0
Incubateur Impulse Accelerator/Incubator 000 0000 000000 0
To view Neurochlore’s complete investors history, request access »